Table 1

Reported efficacy of rituximab in nonrandomised trials of systemic lupus erythematosus

Study

Rituximab regimen

Organ-specific disease

Number of patients/follow-up (months)

Method of assessment (mean disease activity score before/after B-cell depletion)


Anolik and colleagues [64]; Looney and colleagues [26]

Variable

No (7 LN)

17/12

SLAM improved in patients achieving effective B-cell depletion (6.8/5.2)

Leandro and colleagues [15]b

2-dose

No (17/19 LN)

19/6

BILAG (13.9/5)

Vigna-Perez and colleagues [65]

2-dose

Yes, LN

22/3

Mexico-SLEDAI (10.8/6.8)

Cambridge and colleagues [21]b

2-dose

No (12/15 LN)

15/6

BILAG

Tamimoto and colleagues [66]

Variable

No (4/8LN)

8

SLEDAI (17.6/7.3)

Tokunaga and colleagues [28]

Variable

Yes, NPSLE

10/7 to 45

Neurological parameters (GCS)

Tanaka and colleagues [67]

2-dose

No (6LN)

14/7

BILAG (12.5/7.1)

Ng and colleagues [17]b

2-dose

No (21 LN)

32/39

BILAG (13/5)

Reynolds and colleagues [45]

Variable

No

11/10

BILAG (median reduction of 7.5)

Li and colleagues [68],

2-dose

Yes, LN

19/12

SLEDAI (9.2/2.5)

Lu and colleagues [69]b

2-dose

No (33/45 LN)

45/39.6

BILAG (12/5)

Pepper and colleagues [56]

2-dose + MMF maintenance

Yes, LN

20/12

Renal parameters improved in 14/18 at 12 months

Catapano and colleagues [19]

4-dose (15) or2-dose + CYC (16)

No (11 LN)

31/30

BILAG (14.5/3.5 at 24 months)

Sfikakis and colleagues [70]

4-dose

Yes, LN

10/12

Renal parameters

Gottenberg and colleagues [71]

4-dose

No (4 LN)

13/8.3

SLEDAI (8/2)

Smith and colleagues [18]

4-dose, retreated with 2-dose

No

11/24

BILAG (14/2)

Gunnarsson and colleagues [72]

4-dose

Yes, LN

7/6

SLEDAI (15/3)

Galarza and colleagues [73]

4-dose

No

43/12

SLEDAI (12.5/4.5)

Jonsdottir and colleagues [74]

4-dose

No (10 LN)

16/27

SLEDAI (12.1/4.7)

Lindholm and colleagues [75]

4-dose

No (17 LN)

29/22

Renal parameters

Sutter and colleagues [76]

4-dose

No

12

SLEDAI (9/5)

Boletis and colleagues [77]

4-dose

Yes, LN

10/38

Renal parameters

Melander and colleagues [78]

4-dose regimen (10 retreated)

Yes, LN

20/22

12/20 improved


BILAG, British Isles Lupus Assessment Group; CYC, cyclophosphamide; GCS, Glasgow Coma Scale; MMF, mycophenolate mofetil; SLAM, systemic lupus activity measure; LN, lupus nephritis; NPSLE, neuropsychiatric systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. aRandomised controlled trial. bSame cohort in these studies.

Reddy et al. Arthritis Research & Therapy 2013 15(Suppl 1):S2   doi:10.1186/ar3910